When the maximum-tolerated dose in the combination setting is determined, additional patients with advanced solid malignancies will be enrolled to a dose expansion portion to explore further the safety, tolerability, pharmacokinetics (PK), and biological activity at the selected doses. Approximately 24 to 36 patients with advanced solid malignancies will be treated in Phase 1a.